The Technical Analyst
Xeris Pharmaceuticals Inc [XERS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Xeris Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.12% $1.760
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 247.20 mill |
| EPS: | -0.450 |
| P/E: | -3.91 |
| Earnings Date: | Mar 05, 2024 |
| SharesOutstanding: | 140.45 mill |
| Avg Daily Volume: | 1.917 mill |
| RATING 2024-04-24 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.91 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.67x |
| Company: PE -3.91 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.629 - 1.911 ( +/- 7.97%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | Sherman Jeffrey W | Buy | 6 502 | Common Stock |
| 2024-03-15 | Kong Garheng | Buy | 6 474 | Common Stock |
| 2024-03-15 | Johnson John | Buy | 89 571 | Common Stock |
| 2024-03-18 | Johnson John | Buy | 215 600 | Common Stock |
| 2024-03-18 | Johnson John | Sell | 215 600 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 92.72 |
| Last 99 transactions |
| Buy: 12 203 668 | Sell: 238 056 |
Forecast:
16:00 - $1.760
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.760
Forecast 2: 16:00 - $1.760
Forecast 3: 16:00 - $1.760
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.760 (-1.12% ) |
| Volume | 0.694 mill |
| Avg. Vol. | 1.917 mill |
| % of Avg. Vol | 36.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XERS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.70 | N/A | Active |
|---|
XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Last 10 Buy Signals
Latest Press Releases
2024-04-03 16:05:00 - Press Release
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chicago--(business wire)-- #gvokehypopen--xeris biopharma holdings, inc. (nasdaq: xers), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on april 1, 2024, the compensation committee of xeris' board of directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under xeris' inducement equity plan. xeris' inducement equi.
2024-04-02 07:00:00 - Press Release
Xeris Biopharma To Participate In The 23rd Annual Needham Virtual Healthcare Conference
Chicago--(business wire)-- #gvokehypopen--xeris biopharma holdings, inc. (nasdaq: xers), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that paul r. edick, xeris' chairman and ceo, will present an overview of the company at the 23rd annual needham virtual healthcare conference on tuesday, april 9, 2024 at 11:00 am eastern time. to access the presentation, please visit “events”.
2024-03-06 07:02:00 - Press Release
Xeris Biopharma Reports Fourth Quarter And Full Year 2023 Financial Results And Recent Events
Chicago--(business wire)-- #gvokehypopen--xeris biopharma holdings, inc. (nasdaq: xers), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended december 31, 2023 and recent events. “2023 was another year of exceptional performance and growth for xeris. we executed on all fronts: our commercial products grew over 40%; our intern.
2024-03-06 07:00:00 - Press Release
Xeris Refinances Its $150m Senior Secured Term Loan Facility With Hayfin Capital
Chicago--(business wire)-- #gvokehypopen--xeris biopharma holdings, inc. (nasdaq: xers), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced it has entered into an amended and restated senior secured term loan agreement (“debt facility”) with funds managed by hayfin capital management llp (“hayfin”) to provide xeris $200.0 million of capital at close and the ability to draw down ano.
2024-02-28 07:00:00 - Press Release
Xeris Biopharma To Report Fourth Quarter And Full Year 2023 Financial Results On March 6, 2024
Chicago--(business wire)-- #gvokehypopen--xeris biopharma holdings, inc. (nasdaq: xers), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the company will release its fourth quarter and full year 2023 financial results before the open of the u.s. financial markets on wednesday, march 6, 2024. management will host a conference call and webcast at 8:30 a.m. eastern time that d.
Latest News
2024-03-30 01:28:53 - Seeking Alpha
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growth. Risks include competition from larger healthcare companies and the FDA approval of a generic version of one of Xeris' products, Keveyis.
2024-03-06 09:57:54 - Proactive Investors
Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jump
Xeris Biopharma Holdings (NASDAQ:XERS) has bolstered its financial position through the refinancing of its debt with Hayfin Capital Management LLP, securing substantial capital upfront while reducing borrowing interest rates. Under this agreement, Xeris secured $200 million in capital upfront, with the option to access an additional $15.2 million to redeem its outstanding convertible senior notes due in 2025.
2024-03-06 09:16:03 - Zacks Investment Research
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
2024-03-05 10:46:07 - Zacks Investment Research
Why Xeris (XERS) Might Surprise This Earnings Season
Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2024-02-05 07:00:00 - Business Wire
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:00 am Eastern Time. To access the presentation, please v.
2024-01-11 09:47:17 - Zacks Investment Research
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.
2024-01-10 10:52:51 - Proactive Investors
Xeris Biopharma inks exclusive worldwide license agreement with Amgen for XeriJect in thyroid eye disease
Xeris Biopharma Holdings (NASDAQ:XERS) announced an exclusive worldwide license agreement with Amgen for the development, manufacturing, and commercialization of a subcutaneous formulation of teprotumumab using Xeris' XeriJect technology. The collaboration aims to address Thyroid Eye Disease (TED), a severe, progressive, and potentially vision-threatening rare autoimmune disorder.
2024-01-10 10:41:08 - InvestorPlace
Why Is Xeris Biopharma (XERS) Stock Up 12% Today?
Xeris Biopharma (NASDAQ: XERS ) stock is heading higher on Wednesday after the company announced an exclusive worldwide license agreement with Amgen (NASDAQ: AMGN ). That agreement allows Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab, known as TEPEZZA in the U.S. This will be done with Xeris Biopharma's XeriJect technology for Thyroid Eye Disease.
2024-01-09 01:07:03 - Seeking Alpha
Xeris Biopharma: Speculative Buy, Size Your Position Accordingly
Xeris Biopharma Holdings focuses on developing and commercializing therapies in endocrinology, neurology, and gastroenterology using their proprietary formulation platforms. Their formulation platforms, XeriSol and XeriJect, address limitations of aqueous formulations for certain drugs, improving stability and solubility. The company has seen significant revenue growth, with three commercially approved drugs generating $42 million in revenues in Q3 2023.
2024-01-08 14:48:03 - InvestorPlace
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
2023 was dominated by the Magnificent Seven stocks, which has left investors wondering how much higher mega-cap stocks can go. Investors worry that growth is nearing a peak or perhaps reversing.